Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Biodesix (BDSX) EBITDA Margin (2019 - 2026)

Biodesix filings provide 8 years of EBITDA Margin readings, the most recent being 24.27% for Q1 2026.

  • On a quarterly basis, EBITDA Margin rose 2661.0% to 24.27% in Q1 2026 year-over-year; TTM through Mar 2026 was 25.95%, a 1785.0% increase, with the full-year FY2025 number at 31.5%, up 1687.0% from a year prior.
  • EBITDA Margin hit 24.27% in Q1 2026 for Biodesix, down from 6.84% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 6.84% in Q4 2025 to a low of 220.85% in Q1 2022.
  • Median EBITDA Margin over the past 5 years was 50.87% (2025), compared with a mean of 76.65%.
  • Biggest five-year swings in EBITDA Margin: plummeted -20150bps in 2022 and later soared 10642bps in 2024.
  • Biodesix's EBITDA Margin stood at 144.58% in 2022, then soared by 68bps to 46.84% in 2023, then surged by 31bps to 32.55% in 2024, then skyrocketed by 79bps to 6.84% in 2025, then plummeted by -255bps to 24.27% in 2026.
  • The last three reported values for EBITDA Margin were 24.27% (Q1 2026), 6.84% (Q4 2025), and 32.39% (Q3 2025) per Business Quant data.